Halozyme Therapeutics Announced US FDA Approval for Janssen Biotech's DARZALEX FASPRO®
Halozyme Therapeutics (HALO) announced that Janssen Biotech, Inc. (Janssen) received U.S. FDA approval of DARZALEX FASPRO® (daratumumab + hyaluronidase-fihj) in combination with pomalidomide and dexamethasone (Pd) for adult patients with multiple myeloma who have received at least one prior line of therapy, including . . .
This content is for paid subscribers.
Today’s Highlights July 13, 2021